- “Medarex gets payment after Ilaris approval” (Forbes)
- “CytRx files FDA report on halted clinical trial” (MarketWatch)
- “J&J unit gets $1.67 billion verdict vs Abbott Labs” (The Associated Press)
Read the rest of this entry »
THE LATEST WORD
Top Industry Stories – June 30, 2009
Posted on June 30th, 2009 | by Rxmedyn | No Comments »Posted in Industry Stories
Top Industry Stories – June 29, 2009
Posted on June 29th, 2009 | by Rxmedyn | No Comments »- “ABRAXANE Approved for Advanced Breast Cancer Patient Treatment in Quebec” (Press release issued by Abraxis BioScience, Business Wire)
- “Forum Exchanges Ideas Impacting Drug Approvals” (San Diego Business Journal)
- “Israel sets up 1 billion shekel biotech fund” (Reuters)
Read the rest of this entry »
Posted in Industry Stories
Top Industry Stories – June 26, 2009
Posted on June 26th, 2009 | by Rxmedyn | No Comments »Posted in Industry Stories
Top Industry Stories – June 25, 2009
Posted on June 25th, 2009 | by Rxmedyn | No Comments »- “Teva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial” (Press release issued by Teva Pharmaceuticals, PR-Inside.com)
- “New Cancer Drug Reports Success in Trials” (Top News – United States)
- “Pfizer’s Sutent effective vs rare pancreatic cancer” (Reuters)
Read the rest of this entry »
Posted in Industry Stories
Top Industry Stories – June 24, 2009
Posted on June 24th, 2009 | by Rxmedyn | No Comments »- “Europe aims to reduce cancer deaths by 15 pct by 2012” (Reuters)
- “US FDA staff: Problems in River Plate drug studies” (Reuters)
- “FDA says Ista eye drug has no serious side effects” (The Associated Press)
Read the rest of this entry »
Posted in Industry Stories
Top Industry Stories – June 23, 2009
Posted on June 23rd, 2009 | by Rxmedyn | No Comments »- “Groundbreaking Skin Care Technology Debuts in Wrinkle Reversing Serum from Skin Authority” (Press release issued by Skin Authority, PR Web)
- “Local Researcher Shows Botox Clears Up Acne!” (Press release issued by Dr Michael Breen Associates, Medical News Today)
- “Abbott says new Xience stent approved in Europe” (Reuters)
Read the rest of this entry »
Posted in Industry Stories
Top Industry Stories – June 22, 2009
Posted on June 22nd, 2009 | by Rxmedyn | No Comments »- “Bayer says contraceptive pill sales up as planned” (Reuters)
- “NanoViricides, Inc. CEO Invited to Speak at NanoBio 2009 Conference” (Press release issued by NanoViricides, BusinessWire)
- “Pending FDA Decisions: 20 Extreme Trades” (Seeking Alpha)
- “Bioniche amends credit facility” (Reuters)
- “Merck to test stimuvax cancer drug in Phase III” (Reuters)
- “Andromeda says Teva to market diabetes treatment” (Reuters)
- “Gastric cancer incidence low, but diagnosis often late” (Baltimore Sun)
- “Family raising awareness about cystic fibrosis” (Newnan Times-Herald)
- “Merck & Co to sell $3.5 bln debt in 4 parts – IFR” (Reuters)
Posted in Industry Stories
Top Industry Stories – June 19, 2009
Posted on June 19th, 2009 | by Rxmedyn | No Comments »Posted in Industry Stories
Top Industry Stories – June 18, 2009
Posted on June 18th, 2009 | by Rxmedyn | No Comments »- “Allergan Receives FDA Approval for OZURDEX™ Biodegradable, Injectable Steroid Implant with Extended Drug Release for Retinal Disease” (Press release issued by Allergan, BusinessWire)
- “Biotech Set to Dominate Drug Industry Growth” (Seeking Alpha)
- “JNJ says review of Cougar Biotech deal is complete” (Forbes)
-
Read the rest of this entry »
Posted in Industry Stories
Top Industry Stories – June 17, 2009
Posted on June 17th, 2009 | by Rxmedyn | No Comments »- “Allergan (AGN) PriceWatch Alert Up To 13.53% Downside Protection” (Market Intelligence Center)
- “Results of Integrative Breast Cancer Treatment Program Announced 12-Year Study Shows Doubling of Life Expectancy” (Press release issued by The Block Center for Integrative Cancer Treatment, PR Web)
- “Biggest Shift in U.S. Health Care May Emerge in 45-Day Sprint” (Bloomberg)
- “New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out-of-Pocket Costs Not Filling Prescriptions” (Market Watch)
- “Neuromed Announces Sale of U.S. Rights to Drug Candidate Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) to Mallinckrodt” (Press release issued by Neuromed, PR Newswire)
Posted in Industry Stories
SUBSCRIBE-
Recent Posts
Archives
Careers | © 2009 Medical Dynamics